Skip to content

AMGN · AMGEN INC

34 filings

10-K

AMGN 10-K Annual Reports

AMGEN INC - 34 annual reports

Filing record · 2016–202610-K1210-Q328-K125

2025
AMGEN INC Annual Report, Year Ended Dec 31, 2025
Amgen's FY2025 10-K shows a company in transition: total revenues rose 10% to $36.8 billion, product sales grew 10% to $35.1 billion on 13% volume growth (offset by a 3% net price decline), and diluted EPS more than doubled to $14.23 from $7.56. Net income reached $7.7 billion, helped by $2.1 billion of unrealized equity gains (primarily the BeOne stake), a $1.2 billion Otezla intangible impairment, and lower amortization from the Horizon acquisition. Operating cash flow was $10.0 billion, with $1.9 billion of capex and $6.0 billion of debt retired, though stockholders' equity remains modest at $8.7 billion with an accumulated deficit. Growth is concentrated in newer launches: Repatha (+36%), TEZSPIRE (+52%), EVENITY (+34%), BLINCYTO (+28%), and IMDELLTRA. These offset steep erosion in ENBREL (-33%), driven by 340B mix, Medicare Part D redesign, and discounting, and an expected accelerated decline in Prolia and XGEVA as denosumab biosimilars launch after patent expiry. Policy headwinds are significant: IRA Medicare price setting begins with ENBREL in 2026 and Otezla in 2027, and MFN-related pricing commitments, state PDAB upper payment limits, and 340B expansion all pressure net pricing. Key risks include the IRS transfer-pricing dispute (about $3.6B and $5.1B in proposed federal tax plus penalties for 2010-2015, with a Tax Court decision not expected before H2 2026), the TAVNEOS FDA withdrawal request and Amgen's decision to contest it, the Regeneron antitrust verdict ($406.8M claimed), and the Otezla impairments. Management is investing heavily in R&D ($7.3 billion, up 22%), with six Phase 3 MariTide studies underway, and in U.S. manufacturing.
Feb 13, 2026
2024
AMGEN INC Annual Report, Year Ended Dec 31, 2024
Amgen's FY2024 10-K (filed February 14, 2025) shows a company whose top line grew strongly but whose profitability fell sharply. Total revenues rose 19% to $33.4 billion, driven by product sales of $32.0 billion, with volume growth of 23% offsetting a 2% decline in net selling price. The Horizon Therapeutics acquisition (closed October 2023) contributed $4.2 billion of product sales in 2024, and new launches such as TEZSPIRE, BLINCYTO, TEPEZZA, and Repatha grew rapidly. However, GAAP net income fell 39% to $4.1 billion and diluted EPS fell to $7.56 from $12.49, pressured by higher cost of sales (38.5% of revenue, up from 30.0%) driven by amortization of Horizon intangibles and inventory step-up, along with higher interest expense ($3.2 billion) and unrealized losses on equity investments. The outlook carries clear headwinds. Prolia and XGEVA face biosimilar competition after their RANKL patents expired in February 2025 in the U.S., and ENBREL's Medicare price set by CMS takes effect in 2026, with Otezla selected for price setting in 2027. Management also flags continued payer consolidation, 340B expansion, and state-level PDAB actions as pressures on net pricing. Balance-sheet leverage remains significant, with roughly $60.1 billion of total debt against $5.9 billion of stockholders' equity, though operating cash flow of $11.5 billion and a $2.38 quarterly dividend (up 6%) signal continued capacity to service obligations. Pipeline catalysts include MariTide (obesity, up to ~20% weight loss at 52 weeks in Phase 2), UPLIZNA (IgG4-RD PDUFA April 3, 2025), and rocatinlimab in atopic dermatitis. Material legal and tax risks remain unresolved. The IRS transfer-pricing dispute covering 2010–2015 seeks roughly $3.6 billion plus interest for 2010–2012 and $5.1 billion plus about $2.0 billion in penalties for 2013–2015, with a Tax Court decision not expected before 2026. Several biosimilar patent suits over denosumab and aflibercept are ongoing, and securities and derivative litigation tied to the tax disclosures continues.
Feb 14, 2025
2023
AMGEN INC Annual Report, Year Ended Dec 31, 2023
Amgen's FY2023 10-K shows a transformative but leveraged year. Total revenues rose 7% to $28.2 billion and product sales grew 9% to $26.9 billion, driven by volume growth in Repatha, TEZSPIRE, EVENITY, Prolia and BLINCYTO, plus $954 million of product sales from Horizon after its October 6, 2023 closing. GAAP operating income fell 17% to $7.9 billion, however, because of higher cost of sales from Horizon-related amortization, a $783 million AMG 340 impairment, and higher SG&A. Net income rose 3% to $6.7 billion and diluted EPS reached $12.49. Operating cash flow was $8.5 billion, down from $9.7 billion, reflecting Horizon transaction and integration payments. The key investor issue is the balance sheet. The $27.8 billion Horizon acquisition was funded mainly by $24 billion of senior notes and a $4 billion term loan, pushing long-term debt to $63.2 billion from $37.4 billion. Stockholders' equity was only $6.2 billion, and the company has an accumulated deficit. Management stated that S&P, Moody's and Fitch ratings were BBB+, Baa1 and BBB, all still investment grade, but the filing acknowledges downgrades. Management plans to reduce leverage before returning to debt markets, and it paused share buybacks in 2023 while keeping the quarterly dividend, raised 10% to $2.13 per share for 2023 and to $2.25 for Q1 2024. The main medium-term risks are concentrated. Three wholesalers account for 79% of gross revenue, and the top PBMs and insurers control about 92% of prescriptions. The IRA's Medicare price-setting begins in 2026 with ENBREL selected, and biosimilar competition is intensifying for ENBREL, EPOGEN, Neulasta and others. The company also faces a large IRS tax dispute covering 2010–2015, with Tax Court trial set for November 2024 and $3.6 billion plus $5.1 billion of asserted federal tax and about $2.0 billion of penalties. Pipeline catalysts include the tarlatamab BLA decision (PDUFA June 12, 2024), while the LUMAKRAS full-approval application received a Complete Response Letter.
Feb 14, 2024
2022
AMGEN INC Annual Report, Year Ended Dec 31, 2022
Amgen's FY2022 10-K (filed February 9, 2023) shows a company with stable core revenue and strong cash generation, but with a heavy near-term balance sheet load tied to its pending Horizon Therapeutics acquisition. Total revenues rose 1% to $26.3 billion and product sales rose 2% to $24.8 billion, driven by volume growth in Repatha, Prolia, EVENITY, Nplate, and Tezspire, partly offset by net price erosion and biosimilar pressure on Neulasta, ENBREL, and MVASI. Diluted EPS rose 18% to $12.11, helped by lower acquired IPR&D expense versus 2021 (which had a $1.5 billion Five Prime charge). Operating cash flow was $9.7 billion, and the company returned capital through $4.2 billion in dividends and $6.4 billion in buybacks. The key investor issue is leverage and deal risk. Long-term debt rose to $37.4 billion, and stockholders' equity fell to $3.7 billion from $6.7 billion, reflecting buybacks and an accumulated deficit. The $27.8 billion Horizon acquisition is financed with bridge and term loan commitments totaling $28.5 billion, and the FTC issued a Second Request in January 2023, which extends the regulatory review. Management guides to continued net price declines in 2023, and ENBREL and Neulasta face ongoing erosion, so the company's growth depends on newer launches and on the Horizon transaction closing. Risk items to monitor include the IRS tax dispute covering 2010-2015 (Notices seeking roughly $8.7 billion of additional federal tax plus penalties and interest, partly offset by repatriation tax), Medicare drug price negotiation under the Inflation Reduction Act starting in 2026, and patent litigation on Otezla and Repatha. Amgen's manufacturing concentration in Puerto Rico and Thousand Oaks is also a noted operational risk.
Feb 9, 2023
2021
AMGEN INC Annual Report, Year Ended Dec 31, 2021
Amgen's FY2021 10-K shows a company with flat total product sales of $24.3 billion (U.S. down 4% to $17.3 billion, ROW up 12% to $7.0 billion) while operating income fell 16% to $7.6 billion and diluted EPS declined 16% to $10.28, reflecting lower net selling prices from biosimilar and generic competition, a $1.5 billion acquired IPR&D charge for the Five Prime acquisition (bemarituzumab), and higher cost of sales. Total revenues rose 2% to $26.0 billion, aided by growth in Prolia, Repatha, Nplate, Otezla and TEZSPIRE, offset by declines in Neulasta (down 24%), ENBREL (down 11%) and Parsabiv. Management expects continued net price erosion in 2022 as biosimilar competition intensifies, with Amgen's own biosimilars (MVASI, KANJINTI, AMGEVITA, AVSOLA, RIABNI) partly offsetting that pressure in new markets. Capital allocation remained shareholder-focused: operating cash flow of $9.3 billion funded $5.0 billion of buybacks, $4.0 billion of dividends (quarterly dividend raised 10% to $1.76 per share, and to $1.94 for Q1 2022), and $880 million of capex, with the Board adding $12.9 billion to the repurchase authorization during 2021. Stockholders' equity fell to $6.7 billion and the company carries an accumulated deficit, a consequence of buybacks and dividends exceeding earnings, but management states this does not impair its ability to operate or service $33.3 billion of long-term debt, rated A-/Baa1/BBB+ by S&P, Moody's and Fitch. Investors should also weigh a large contingent tax exposure: the IRS has asserted approximately $3.6 billion of additional federal tax (plus interest) for 2010 to 2012 over Puerto Rico profit allocation, with similar 2013 to 2015 adjustments expected, and Amgen is contesting these in U.S. Tax Court. Key forward-looking risks include U.S. drug-pricing reform (IRA-style negotiation proposals, rebate reform, copay-assistance restrictions), biosimilar erosion of Neulasta, EPOGEN and ENBREL, concentration of sales among three wholesalers (82% of gross revenue), and Puerto Rico manufacturing exposure. Amgen's R&D spend rose to $4.8 billion, and the company's 13 phase 3 programs and newly approved indications (LUMAKRAS, TEZSPIRE, Otezla psoriasis expansion) represent the main pipeline catalysts.
Feb 16, 2022
2020
AMGEN INC Annual Report, Year Ended Dec 31, 2020
Amgen's FY2020 10-K (filed February 2021) shows a company in transition: total revenues rose 9% to $25.4 billion, driven by Otezla (acquired November 2019), which generated $2.2 billion in 2020 sales, along with MVASI, KANJINTI, and Repatha. Net income declined 7% to $7.3 billion and diluted EPS fell 4% to $12.31, pressured by higher cost of sales (24.2% of revenues, up from 18.6%) reflecting Otezla intangible amortization, and by a higher effective tax rate on the BeiGene investment and other items. Operating cash flow rose to $10.5 billion, supporting $3.5 billion of buybacks and $3.8 billion of dividends, with the quarterly dividend raised 10% to $1.60 and to $1.76 for Q1 2021. The legacy franchise remains under pressure. ENBREL sales fell 4% to $5.0 billion amid share loss to biosimilars, Neulasta fell 29% to $2.3 billion as biosimilar competition intensified, and Aranesp and EPOGEN declined. Management expects continued net price declines in 2021, more biosimilar launches (including RIABNI, launched January 2021), and additional pricing headwinds from U.S. policy, including the CMS end of TDAPA for calcimimetics and proposed most-favored-nation rules that remain under litigation. Concentration risk is notable: three wholesalers account for 83% of gross revenues, and DaVita accounts for roughly 90% of EPOGEN sales. The pipeline offers potential upside. Sotorasib (KRAS G12C) received Breakthrough Therapy designation and an NDA under the FDA's RTOR program, with a confirmatory phase 3 underway, and tezepelumab's phase 3 NAVIGATOR trial met its primary endpoint, though the SOURCE trial missed. Amgen also faces significant legal and tax overhangs, including IRS Puerto Rico profit-allocation disputes for 2010-2015 and $5.6 billion of remaining repatriation tax payments, plus the Novartis Aimovig litigation and multiple patent cases. Total debt stood at $33.0 billion, with investment-grade ratings (A-/Baa1/BBB+).
Feb 9, 2021
2019-A
AMGEN INC Annual Report (Amendment), Year Ended Dec 31, 2019
Amgen Inc. (AMGN) filed its Annual Report (Form 10-K) for the fiscal year ended December 31, 2019. This filing's primary purpose was to include the conformed signature of its independent auditor, Ernst & Young LLP, which was inadvertently omitted from the original filing. Therefore, this amended filing does not contain new financial information or reflect events occurring after the original filing date of February 12, 2020. Investors should refer to the original Form 10-K for comprehensive financial details. The audit report from Ernst & Young LLP expresses an unqualified opinion on Amgen's consolidated financial statements for the years ended December 31, 2019 and 2018, and its internal control over financial reporting as of December 31, 2019. Two critical audit matters were highlighted: the estimation of sales deductions and the accounting for unrecognized tax benefits, both involving significant management judgment and complexity.
Feb 13, 2020
2019
AMGEN INC Annual Report, Year Ended Dec 31, 2019
Amgen's FY2019 10-K (filed February 12, 2020) shows a company in transition. Total revenues fell 2% to $23.4 billion, with total product sales down 1% to $22.2 billion. U.S. product sales declined 5%, while rest-of-world sales rose 11%. The decline reflects lower net selling prices and growing biosimilar and generic competition, most visibly for Neulasta (down 28%), Sensipar (down 69%, after generic entry) and EPOGEN (down 14%). Growth came from Prolia (up 17%), XGEVA (up 8%), KYPROLIS (up 8%) and a broad 'other products' category that rose 49%, driven largely by newer launches such as Otezla, which Amgen acquired from Celgene for $13.4 billion in November 2019. Management expects net selling prices to keep declining in 2020 and expects lower unit demand for ENBREL and Aranesp. Profitability softened but remained strong. Operating income fell 6% to $9.7 billion and net income declined 7% to $7.8 billion. Diluted EPS nevertheless rose 2% to $12.88, helped by a 8% reduction in diluted shares to 609 million after $7.6 billion of buybacks. R&D spending rose 10% to $4.1 billion to support oncology, and SG&A fell 3%. Operating cash flow was $9.2 billion, down from $11.3 billion, and the dividend was raised 10% to $1.45 per quarter for 2019 and to $1.60 for the first quarter of 2020. The balance sheet became more leveraged. Cash and marketable securities fell to $8.9 billion from $29.3 billion, mainly to fund the Otezla acquisition and the $2.8 billion BeiGene stake. Total debt declined to $29.9 billion, but stockholders' equity shrank to $9.7 billion from $12.5 billion, leaving an accumulated deficit. Key risks include the unresolved IRS dispute over Puerto Rico profit allocation, biosimilar litigation on ENBREL, KYPROLIS and MVASITM, U.S. drug-pricing legislation (H.R. 3), and dependence on the Puerto Rico and Thousand Oaks manufacturing sites.
Feb 12, 2020
2018
AMGEN INC Annual Report, Year Ended Dec 31, 2018
Amgen's FY2018 10-K (filed February 13, 2019) shows a company with stable core revenue but a sharply reshaped balance sheet and a heavy near-term exposure to biosimilar and generic erosion. Total revenues rose 4% to $23.7 billion and product sales rose 3% to $22.5 billion, driven by Prolia, XGEVA, Repatha, KYPROLIS and newer launches such as Aimovig and Parsabiv. Operating income increased 3% to $10.3 billion, though SG&A grew 9% to $5.3 billion to support launches. U.S. product sales grew only 2%, while rest-of-world grew 9%. Legacy franchises are declining: ENBREL fell 8%, Neulasta 1%, Aranesp 9% and EPOGEN 8%, and management expects further declines in 2019 as biosimilars and generics enter. Net income was $8.4 billion, or $12.62 diluted EPS, versus $2.0 billion in 2017. That comparison is distorted by the $6.1 billion net charge from the 2017 Tax Act; the effective tax rate fell to 12.1% from 79.4%. Cash from operations was $11.3 billion. Amgen returned capital aggressively, repurchasing $17.9 billion of stock (94.5 million shares, including a $10.0 billion tender offer) and paying $3.5 billion in dividends, and it raised the quarterly dividend 15% to $1.32, with a further increase to $1.45 declared for Q1 2019. Stockholders' equity fell to $12.5 billion from $25.2 billion and the accumulated deficit reached $18.0 billion, a result of buybacks and the repatriation-tax-related accounting rather than operating weakness. Total debt was $33.9 billion, and the company retains investment-grade ratings (A / Baa1 / BBB). Key risks for investors include an unresolved IRS Revenue Agent Report on Puerto Rico profit allocation for 2010–2012, a repatriation tax of $6.7 billion payable over eight years, pricing pressure from PBM consolidation and U.S. drug-pricing policy, Puerto Rico manufacturing exposure, and numerous patent and biosimilar litigations (including Sensipar generics, KYPROLIS ANDAs, Sandoz ENBREL, and Hospira EPOGEN). Pipeline catalysts for 2019 include the FDA decision on EVENITY, tezepelumab's Phase 3 program, and biosimilar filings for ABP 710 and ABP 798.
Feb 13, 2019
2017
AMGEN INC Annual Report, Year Ended Dec 31, 2017
Amgen's 2017 Form 10-K (filed February 13, 2018) shows a year of stable top-line results but sharply lower GAAP earnings, driven by a one-time tax charge. Total revenues were $22.85 billion, down 1% from $22.99 billion, with product sales flat at $21.8 billion. U.S. product sales fell 1% on lower unit demand from competition, partly offset by higher net prices, while rest-of-world sales grew 2%. Operating income rose 2% to $9.97 billion, helped by a 2% decline in operating expenses from transformation savings. Net income, however, collapsed 74% to $1.98 billion ($2.69 diluted EPS) because of a $6.1 billion net charge from the 2017 Tax Act, which included a $7.3 billion repatriation tax payable over eight years. The effective tax rate was 79.4%. Excluding the tax charge, the underlying business looks considerably more stable than headline EPS suggests. Key product trends are mixed. ENBREL sales fell 9% to $5.4 billion on lower unit demand and net price, and management expects those trends to continue in 2018. EPOGEN fell 15% after a DaVita contract reset. Growth came from Prolia (+20%), Sensipar/Mimpara (+9%), XGEVA (+3%), and newer launches such as Repatha, which more than doubled to $319 million. Several patent-protected franchises face erosion, including Neulasta (no material U.S. patent after October 2015), EPOGEN, and Sensipar's composition-of-matter patent expiring March 2018, plus growing biosimilar competition. Pipeline and regulatory news was active, including the Repatha cardiovascular outcomes label, a May 2018 PDUFA date for Prolia in glucocorticoid-induced osteoporosis, and a May 2018 PDUFA for Aimovig in migraine prevention. Capital return was also substantial: a 15% dividend increase, $3.1 billion of 2017 buybacks, and a new $10 billion authorization with a $10 billion tender offer announced February 5, 2018. Cash, cash equivalents and marketable securities were $41.7 billion, against total debt of $35.3 billion.
Feb 13, 2018
2016
AMGEN INC Annual Report, Year Ended Dec 31, 2016
Amgen's 2016 Form 10-K (filed February 14, 2017) shows a financially strong year: total revenues rose 6% to $22.99 billion, net income grew 11% to $7.72 billion, and diluted EPS increased 13% to $10.24. Product sales grew 5% to $21.89 billion, led by ENBREL (+11% to $5.97 billion), Prolia (+25%), Sensipar/Mimpara (+12%) and XGEVA (+9%), offset by steep declines in EPOGEN (-31%) and NEUPOGEN (-27%) from competition and biosimilars. Operating income rose 16% to $9.79 billion, and operating cash flow grew 6% to $10.4 billion, funding a 27% dividend increase to $1.00 per quarter (with a $1.15 quarterly dividend declared for Q1 2017) and $3.0 billion of buybacks. The filing also flags a more challenging outlook. Management expects 2017 to be "increasingly challenging," with intensifying ENBREL competition, little benefit from net price increases, and rising biosimilar pressure on several franchises. Neulasta faces U.S. competition after its final material patent expired in October 2015, and the company is exposed to U.S. drug-pricing policy shifts, PBM formulary pressure (Repatha access has been constrained by utilization management), and reliance on a concentrated set of wholesalers and dialysis customers. Total debt rose to $34.6 billion, though the company carries investment-grade ratings (A / Baa1 / BBB). Pipeline news was substantial in early 2017: the FOURIER cardiovascular outcomes trial of Repatha met its primary endpoint, EVENITY has a PDUFA date of July 19, 2017, and the Federal Circuit stayed the injunction against Sanofi/Regeneron's alirocumab pending appeal. Investors will likely focus on whether these catalysts can offset the erosion in legacy biologics and the Puerto Rico and tax-reform uncertainties noted in the filing.
Feb 14, 2017
2015
AMGEN INC Annual Report, Year Ended Dec 31, 2015
Amgen's fiscal 2015 10-K shows a company with strong top-line and profit growth, but facing a major shift in its competitive position. Total revenues rose 8% to $21.7 billion, driven by U.S. product sales growth of 12% to $16.5 billion, largely from price increases and strong demand for ENBREL, Prolia, XGEVA, Sensipar, and Kyprolis. Operating income rose 37% to $8.5 billion, and net income increased 35% to $6.9 billion, or $9.06 per diluted share. Operating cash flow grew 6% to $9.1 billion. Results were helped by lower operating expenses from a restructuring program, which carries an estimated $800 to $900 million in total pre-tax charges and a reduction of 3,500 to 4,000 staff. The key investor concern is patent expiration and biosimilar erosion. 2016 is the first full year Amgen competes without patent protection on several principal U.S. products. Zarxio, a biosimilar to NEUPOGEN, launched in September 2015, and NEUPOGEN and EPOGEN sales declined 9% in 2015, with EPOGEN's U.S. decline accelerating to 37% in the fourth quarter. The final U.S. patents for Neulasta and EPOGEN expired in October 2015 and May 2015, respectively, and additional biosimilars are in development. Rest-of-world product sales fell 4%, partly due to unfavorable foreign exchange. Management is leaning on new launches, including Repatha, Kyprolis, and Blincyto, along with a pipeline that includes several near-term regulatory decisions. Balance sheet and capital return remain strong. Amgen held $31.4 billion in cash and marketable securities against $31.6 billion of total debt, and about $29.0 billion of cash is held outside the U.S. Amgen paid $2.4 billion in dividends, repurchased $1.9 billion of stock, and raised its quarterly dividend 27% to $1.00 for the first quarter of 2016. Investors should weigh the strong 2015 earnings against concentration risk (three wholesalers represent about 97% of U.S. gross sales), pricing and reimbursement pressure, and the Puerto Rico fiscal crisis, which affects a key manufacturing site.
Feb 16, 2016
2014
AMGEN INC Annual Report, Year Ended Dec 31, 2014
Amgen's 2014 10-K shows a company with solid top-line growth and a sharply rising profit base, but with rising costs and a sizable pipeline and patent-expiry overhang. Total revenues rose 7% to $20.1 billion, product sales grew 6% to $19.3 billion (U.S. +5%, ROW +11%), and net income rose 2% to $5.2 billion, or $6.70 diluted EPS. Operating income increased 6% to $6.2 billion. Growth was driven by price increases in the U.S., Kyprolis (added via the Onyx acquisition in October 2013), Prolia and XGEVA, and international unit growth. Offsetting this were a 32% jump in cost of sales (largely non-cash amortization from Onyx) and $558 million of restructuring charges under a plan to cut 3,500 to 4,000 jobs and close facilities in Colorado and Washington, with total charges expected at $935 million to $1,035 million. The effective tax rate rose to 7.6% from 3.5%, which compressed the net income gain relative to operating income. The key investor considerations are the upcoming loss of exclusivity and biosimilar competition. Neulasta and NEUPOGEN face filgrastim and pegfilgrastim biosimilar filings (including Sandoz's ZARXIO, which has an FDA advisory committee recommendation and is in litigation with Amgen), U.S. Neulasta's main patent expires in October 2015, and the remaining EPOGEN patent expires in May 2015. NEUPOGEN sales fell 17% in 2014. Management is pinning long-term growth on a pipeline that includes Repatha (evolocumab), Corlanor, brodalumab, BLINCYTO (accelerated approval December 2014), and the biosimilar program. Cash and marketable securities reached $27.0 billion, against $30.7 billion of debt. Shareholder returns were raised, with the quarterly dividend increased 30% to $0.79 and $3.8 billion remaining on the buyback authorization. Roughly 94% of U.S. gross product sales go through three wholesalers, which concentrates both credit and pricing risk.
Feb 19, 2015
2013
AMGEN INC Annual Report, Year Ended Dec 31, 2013
Amgen's fiscal 2013 10-K shows a company in transition: revenue rose 8% to $18.7 billion, net income rose 17% to $5.1 billion, and diluted EPS grew 20% to $6.64. Growth was led by Prolia and XGEVA (up 45% combined), ENBREL (up 7%), and Neulasta/NEUPOGEN (up 8%), while Aranesp (down 6%) continued to erode under ESA safety-driven label and reimbursement changes. The effective tax rate fell to 3.5%, which flattered earnings. Part of the net income gain reflects one-time items, including a $182 million tax benefit from the Onyx acquisition and a $187 million IRS settlement. Operating income grew only 5%, and the company's share of reported profit growth came largely from the lower tax rate. The Onyx Pharmaceuticals acquisition for roughly $9.5 billion in cash, closed October 1, 2013, is the defining event of the year. It added Kyprolis for multiple myeloma and the Nexavar and Stivarga partnerships, but it was financed almost entirely with debt. Total debt rose to $32.1 billion from $26.5 billion, including an $8.1 billion Master Repurchase Agreement and Term Loan. Management stated it does not expect significant share repurchases in 2014 or 2015, a notable shift after $8.3 billion of buybacks in 2011. Dividends were raised 30% to $0.61 per quarter. Cash, equivalents, and marketable securities of $22.8 billion are largely held offshore, with about $20.9 billion intended to remain outside the U.S. for tax reasons. Looking ahead, investors face a heavy slate of patent expirations and competitive pressures. U.S. filgrastim patents expired in December 2013, Granix launched as a competitor, and MIRCERA is expected to enter the U.S. market in mid-2014. Biosimilars are a growing threat in Europe and an expected threat in the U.S. The pipeline is the main offset, with evolocumab (PCSK9) positive in five phase 3 studies, talimogene laherparepvec and trebananib advancing, and 16 phase 3 programs. The 10-K also discloses a January 2014 FDA warning letter about combination products and a Sandoz patent suit over etanercept. Key risks are the durability of the growth outside Prolia and XGEVA, the leverage taken on for Onyx, and the company's ability to replace Aranesp and Neulasta/NEUPOGEN revenue as exclusivity ends.
Feb 24, 2014
2012-A
AMGEN INC Annual Report (Amendment), Year Ended Dec 31, 2012
This filing is an amendment (10-K/A) to Amgen Inc.'s previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The amendment specifically pertains to Exhibit 10.54, a Collaboration and License Agreement between Amgen and Celltech R&D Limited. The company sought confidential treatment for portions of this exhibit and is refiling it with reduced redactions following discussions with the SEC staff. This amendment does not alter other financial information or disclosures from the original 10-K and is primarily administrative in nature, re-establishing the exhibit with revised confidentiality status.
Jul 31, 2013
2012
AMGEN INC Annual Report, Year Ended Dec 31, 2012
Amgen's 2012 Form 10-K shows a company growing revenue 11% to $17.3 billion, with net income up 18% to $4.3 billion and diluted EPS up 37% to $5.52. Growth was led by ENBREL (sales up 14% to $4.2 billion), XGEVA/Prolia (up to $1.2 billion from $554 million), and Neulasta/NEUPOGEN (up 3% to $5.4 billion). The main offsets were the ESA franchise (Aranesp down 11% and EPOGEN down 5%), driven by 2011 label and reimbursement changes. Higher ENBREL profit-share expense and a Puerto Rico excise tax also pressured gross margin, with cost of sales rising to 17.5% of product sales. The filing highlights medium-term risks that investors should weigh. Patents on NEUPOGEN and EPOGEN expire around late 2013, and the company expects increasing biosimilar competition in the U.S. and Europe. ENBREL's Pfizer co-promotion ends October 2013, and the company faces competition from several newer RA and psoriasis therapies. The company also resolved its federal sales and marketing investigations on December 19, 2012, paying about $612 million in civil settlements and $150 million in criminal fines, and entered a five-year corporate integrity agreement. In January 2013 the RED-HF Aranesp heart-failure trial missed its primary endpoint. Capital allocation remains shareholder-friendly. Amgen repurchased $4.7 billion of stock in 2012 and raised its quarterly dividend 31% to $0.47, payable March 2013. Total debt rose to $26.5 billion, while cash and marketable securities were $24.1 billion. Roughly $18.9 billion of cash sits in foreign jurisdictions, which would face additional U.S. taxes if repatriated. Pipeline progress included four programs advancing to phase 3 (AMG 145, brodalumab, romosozumab, rilotumumab), offset partly by the acquisitions of Micromet, KAI, MN, and deCODE.
Feb 27, 2013
2011
AMGEN INC Annual Report, Year Ended Dec 31, 2011
Amgen Inc. reported strong performance in its 2011 fiscal year, with total revenues reaching $15.58 billion, a 4% increase from the previous year, driven by robust sales of its key products like Neulasta®/NEUPOGEN®, Enbrel®, and other growing products such as Prolia® and XGEVA®. The company demonstrated a strong commitment to shareholder returns, initiating its first-ever quarterly cash dividends in 2011 and repurchasing approximately 15% of its outstanding stock for $8.3 billion. Amgen also made strategic acquisitions, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to expand its pipeline and market reach. However, the company recorded a significant $780 million charge related to an agreement in principle to settle allegations concerning its sales and marketing practices. Looking ahead, Amgen faced ongoing challenges including increasing competition from biosimilars, patent expirations on key products, and evolving regulatory and reimbursement landscapes. Despite these headwinds, the company expressed confidence in its future growth opportunities driven by its late-stage pipeline and strategic business development initiatives.
Feb 29, 2012
2010
AMGEN INC Annual Report, Year Ended Dec 31, 2010
Amgen Inc. reported solid performance in its 2010 10-K filing, with total revenues reaching $15.05 billion, a 3% increase from the previous year. The company's principal products—Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®—continued to be the primary revenue drivers, collectively accounting for approximately 91% of sales in 2010. A significant development highlighted is the launch of Prolia® and XGEVA™ in 2010, representing new growth opportunities. However, Amgen faces ongoing challenges, particularly concerning its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®, due to increased regulatory scrutiny, revised product labeling, and changes in reimbursement policies like the Medicare bundled payment system for dialysis. The company also faces increasing competition from biosimilars in Europe and anticipates similar pressures in the U.S. following the introduction of biosimilar pathways. Amgen remains focused on expanding its pipeline and managing its operational costs effectively amidst these evolving market dynamics.
Feb 25, 2011
2009
AMGEN INC Annual Report, Year Ended Dec 31, 2009
Amgen Inc. reported strong financial results for the fiscal year ended December 31, 2009, demonstrating resilience despite a challenging market environment. The company's primary products, including Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®, continued to drive significant revenue, although Aranesp® sales experienced a notable decline, primarily attributed to updated product labeling related to safety concerns. Despite this, Amgen maintained a robust balance sheet with substantial cash, cash equivalents, and marketable securities, indicating financial strength and flexibility. The company is actively managing its product pipeline, with significant developments expected from its late-stage product candidate, denosumab, which is under regulatory review and has shown promising clinical trial results. Amgen is also navigating a complex regulatory and reimbursement landscape, particularly concerning its erythropoiesis-stimulating agent (ESA) products, which are subject to ongoing scrutiny and potential label changes. Looking ahead, Amgen faces ongoing challenges related to evolving healthcare reforms, increased competition, and regulatory pressures. However, the company's strategic focus on innovation, coupled with its strong financial position, positions it to continue its mission of delivering innovative therapies to patients facing grievous illnesses.
Mar 1, 2010
2008
AMGEN INC Annual Report, Year Ended Dec 31, 2008
Amgen Inc. reported total revenues of $15.0 billion for the fiscal year ended December 31, 2008, representing a 3% increase over the prior year. Net income was $4.2 billion, or $3.90 per diluted share. The company faced significant headwinds, particularly from regulatory and reimbursement developments affecting its erythropoiesis-stimulating agent (ESA) products, including Aranesp® and EPOGEN®. These challenges led to a material adverse impact on Aranesp® sales, especially in the U.S. supportive cancer care setting, and also affected EPOGEN® sales due to revised reimbursement policies. Despite these challenges, Amgen demonstrated resilience with strong sales growth in ENBREL® and Neulasta®/NEUPOGEN®. The company also made progress in its late-stage product candidate pipeline, notably with denosumab, for which a biologics license application was submitted to the FDA in December 2008. Amgen continued to manage its cost structure through restructuring initiatives, incurring $887 million in charges through December 31, 2008, with remaining estimated costs to be incurred in 2009.
Feb 27, 2009
2007
AMGEN INC Annual Report, Year Ended Dec 31, 2007
Amgen Inc.'s 2007 10-K filing highlights a challenging year dominated by significant regulatory and reimbursement headwinds impacting its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®. These challenges, stemming from observed adverse safety results in various studies and subsequent label updates and coverage restrictions by regulatory bodies like the FDA and CMS, led to a substantial reduction in ESA revenues, particularly Aranesp® sales in the U.S. supportive cancer care segment. In response, Amgen initiated a significant restructuring plan, involving staff reductions and operational rationalization, expecting charges of $775 million to $825 million. Despite these setbacks, Amgen reported notable accomplishments, including a successful defense of its intellectual property related to erythropoietin patents against Roche and continued advancement of its pipeline, with positive developments in its denosumab and Nplate™ programs. Strategic collaborations and acquisitions, such as those with Daiichi Sankyo and Takeda, as well as the acquisitions of Alantos and Ilypsa, underscore Amgen's commitment to expanding its R&D capabilities and product pipeline. The company's overall revenues saw a modest increase, driven by strong performance in ENBREL and Neulasta®, though this was substantially offset by the decline in Aranesp® sales. Investors should closely monitor the ongoing impact of regulatory changes, reimbursement policies, and pipeline progress for Amgen's future performance.
Feb 28, 2008
2006
AMGEN INC Annual Report, Year Ended Dec 31, 2006
Amgen Inc.'s 2006 10-K filing highlights a year of significant growth, driven by strong performance in its core therapeutic areas: supportive cancer care, nephrology, and inflammation. The company's principal products, including Aranesp®, Neulasta®, NEUPOGEN®, EPOGEN®, and Enbrel®, continued to generate substantial revenue, contributing 97% of total product sales in 2006. The launch of Vectibix™ in late 2006 marked an expansion into the oncology market. The company reported significant investments in research and development, with R&D expenses increasing by 45% to support its expanding pipeline and late-stage clinical trials. Amgen also completed strategic acquisitions of Abgenix, Inc. and Avidia, Inc. to enhance its capabilities in monoclonal antibodies and novel protein therapeutics, respectively. Despite strong product sales, Amgen faces increasing competition and regulatory scrutiny, particularly concerning reimbursement policies and potential biosimilar products in international markets.
Feb 28, 2007
2005
AMGEN INC Annual Report, Year Ended Dec 31, 2005
Amgen Inc. reported strong financial performance for the fiscal year ending December 31, 2005, with total revenues reaching $12.43 billion and net income of $3.67 billion. The company's growth was primarily driven by its key products: Aranesp®, Enbrel®, and Neulasta®. Amgen continues to invest heavily in research and development, with plans for a significant increase in R&D expenses in 2006 to support its expanding pipeline, particularly for the osteoporosis drug denosumab. The company also announced its intent to acquire Abgenix, Inc. for approximately $2.2 billion, which would further bolster its pipeline with the co-developed drug panitumumab. While the company experienced robust sales growth, it also faces increasing competition, particularly from biosimilar products in Europe, and potential impacts from changes in reimbursement policies, notably the Medicare Modernization Act. Amgen is actively managing its manufacturing capacity and supply chain to meet demand and mitigate risks. The company also continued its share repurchase program, returning significant capital to shareholders.
Mar 10, 2006
2004
AMGEN INC Annual Report, Year Ended Dec 31, 2004
Amgen Inc. reported strong performance in its 2004 annual filing, showcasing significant revenue growth driven by its key therapeutic products. The company's strategic focus on nephrology, supportive cancer care, and inflammatory diseases, supported by blockbuster drugs like EPOGEN®, Aranesp®, Neulasta®, NEUPOGEN®, and ENBREL®, continued to yield substantial sales. The filing highlighted key product developments, including expanded indications and new formulations for ENBREL® and Aranesp®, alongside the introduction of Sensipar® and Kepivancetm. Financially, Amgen demonstrated robust revenue growth, with total revenues reaching $10.55 billion and net income at $2.36 billion for the year. The company also made significant investments in research and development, evidenced by increased R&D expenses and the strategic acquisition of Tularik Inc. for approximately $1.5 billion. However, the company also faced evolving regulatory landscapes, particularly with the Medicare Modernization Act (MMA) potentially impacting future reimbursement rates, and ongoing legal proceedings related to patent and pricing practices, which Amgen believes will not materially affect its financial statements. The company also highlighted its strong liquidity position with substantial cash reserves.
Mar 9, 2005
2003
AMGEN INC Annual Report, Year Ended Dec 31, 2003
Amgen's FY2003 10-K shows a company transformed by the July 2002 Immunex acquisition ($17.8 billion). Total revenues rose 51% to $8,356.0 million and product sales rose 58% to $7,868.2 million, driven by Aranesp, ENBREL, and Neulasta. Net income was $2,259.5 million, or $1.69 diluted EPS, compared with a net loss of $1,391.9 million in 2002, which included a $2,991.8 million write-off of acquired in-process R&D. The comparison is distorted by the acquisition, so 2003 results are the cleaner read on the go-forward earnings base. Growth is concentrated in a few products. ENBREL ($1,300.0 million, co-promoted with Wyeth), Aranesp ($1,543.8 million) and Neulasta ($1,255.0 million) account for most of the increase, while NEUPOGEN declined 8% as patients converted to Neulasta. Costs rose faster than revenue in some lines: cost of sales as a share of product sales climbed to 17.0% from 14.7%, R&D increased 48% to $1,655.4 million, and SG&A increased 34% to $1,952.6 million. Operating cash flow was $3,566.6 million, and capital spending nearly doubled to $1,356.8 million, with 2004 guidance of $1.3–1.5 billion. The filing also flags material risks. These include reimbursement pressure (including the new Medicare Part D law), single-source ENBREL supply dependent on BI Pharma and the Rhode Island plant, European erythropoietin patent expiration in December 2004, a pending Johnson & Johnson arbitration, the TKT/Aventis erythropoietin litigation, and a set of Average Wholesale Price and government pricing investigations. Management states that none of the pending proceedings is expected to have a material adverse effect on the annual consolidated financial statements.
Mar 11, 2004
2002
AMGEN INC Annual Report, Year Ended Dec 31, 2002
Amgen Inc.'s 2002 10-K filing highlights a year of significant growth and strategic expansion, largely driven by the transformative acquisition of Immunex Corporation in July 2002. This acquisition significantly bolstered Amgen's product portfolio and pipeline, particularly in the immunology and inflammation areas, with the addition of ENBREL®. Total revenues increased by 42% to $5.52 billion, fueled by strong performance from key products like Neulasta™, Aranesp®, and EPOGEN®, alongside the initial contribution from ENBREL®. Despite a substantial net loss of $1.39 billion, primarily due to a non-cash write-off of $2.99 billion for acquired in-process research and development related to the Immunex deal, the company's operational performance, excluding this one-time charge, demonstrated robust growth. Amgen maintained a strong financial position with substantial cash reserves, supporting ongoing investments in research and development and strategic initiatives.
Mar 10, 2003
2001
AMGEN INC Annual Report, Year Ended Dec 31, 2001
Amgen's fiscal 2001 10-K shows a company with strong core franchises but a year marked by significant one-time charges and a pending transformational acquisition. Total revenues rose 11% to $4,015.7 million, and product sales grew 10% to $3,511.0 million, driven by EPOGEN/Aranesp ($2,150.0 million, up 10%) and NEUPOGEN ($1,346.4 million, up 10%). Net income increased only about 2% to $1,119.7 million, and diluted EPS fell to $1.03 from $1.05, reflecting a $203.1 million charge for terminating collaboration agreements (notably with Praecis) and a $39.5 million inventory write-off. Excluding these items, earnings would have been meaningfully higher, though the company's cost of sales as a percentage of product sales improved to 12.6%. The balance sheet strengthened, with cash and marketable securities of $2,662.2 million, stockholders' equity rising to $5,217.2 million, and operating cash flow of $1,480.2 million. Management also announced a $3.5 billion zero-coupon convertible note offering (net proceeds about $2.45 billion) and a plan to acquire Immunex for an estimated $17.6 billion, with closing expected in the second half of 2002 subject to FTC and shareholder approvals. Investors should weigh this transaction's dilution, integration risk, and the $475 million termination fee exposure against Amgen's growth prospects. Key risks in the filing include dependence on U.S. ESRD dialysis reimbursement for EPOGEN, the upcoming April 2002 Neulasta launch that may cannibalize NEUPOGEN, pending patent litigation with Transkaryotic Therapies and Aventis, and the Johnson & Johnson arbitration over dialysis market spillover sales. Growth in 2002 is expected to depend largely on Aranesp uptake in new markets and the rollout of Neulasta and Kineret.
Feb 26, 2002
2000
AMGEN INC Annual Report, Year Ended Dec 31, 2000
Amgen closed fiscal 2000 with total revenues of $3,629.4 million (up 9% from $3,340.1 million in 1999) and net income of $1,138.5 million (up 4%), with diluted EPS of $1.05 versus $1.02. Product sales grew only 5% to $3,202.2 million, held back by Year 2000-related wholesaler stocking in late 1999, dialysis provider inventory drawdowns, and adverse foreign exchange. EPOGEN grew 12% to $1,962.9 million on higher dialysis patient volume, while NEUPOGEN declined 3% to $1,223.7 million on wholesaler buying patterns and currency effects. Operating income rose modestly to $1,544.0 million, and reported earnings included a $73.9 million legal award from Johnson & Johnson offset by a $30.1 million in-process R&D write-off (Kinetix acquisition) and a $25 million Amgen Foundation contribution, which had no net impact on reported net income. The balance sheet strengthened considerably, with cash and marketable securities of $2,028.1 million, operating cash flow of $1,634.6 million, and stockholders' equity rising to $4,314.5 million from $3,023.5 million, largely due to employee option exercises and tax benefits. Long-term debt remained modest at $223 million. Management guided to 2001 product sales growth in the mid-to-high teens, with EPOGEN and ARANESP combined sales growing in the high-teens to low-twenties range, NEUPOGEN growing in the high single digits, and EPS growing in the mid-teens. Key risks include potential reimbursement changes from the federal ESRD Program (which funds most EPOGEN use), the timing of the EPOGEN-to-ARANESP transition, pending patent litigation (including the Transkaryotic Therapies/Aventis erythropoietin case and Genentech appeal), and concentration in two wholesalers that account for more than 10% of revenues. The company also announced a $2 billion share repurchase authorization for 2001-2002, funded by strong cash generation, and continued to advance its pipeline, including ARANESP filings with the FDA, abarelix-depot with priority review, and SD/01 phase 3 success in breast cancer. Investors should weigh strong growth prospects and cash generation against heavy reliance on the federal government's ESRD reimbursement and the high-risk nature of the development pipeline.
Mar 7, 2001
1998
AMGEN INC Annual Report, Year Ended Dec 31, 1998
Amgen's 1998 10-K shows a company at a turning point, with strong commercial results but meaningful pipeline setbacks and legal overhang. Total revenues rose 13% to $2,718.2 million in 1998 (from $2,401.0 million), and product sales grew 13% to $2,514.4 million, led by EPOGEN(R) at $1,382.0 million (up 19%), driven by higher dosing and dialysis patient growth. Net income was $863.2 million, or $1.63 diluted EPS (split-adjusted), up from $644.3 million in 1997, which had been depressed by a $157 million Johnson & Johnson spillover charge. Operating cash flow reached $1,041.5 million, and management plans capital expenditures of $300-400 million in 1999. The pipeline picture was more mixed. Amgen discontinued MGDF (platelet growth factor) in September 1998 after neutralizing antibodies emerged, and leptin failed to show a statistically significant weight-loss effect versus placebo in its interim phase 2 analysis. NEUPOGEN(R) also failed a pneumonia-with-sepsis phase 3 study in January 1999. Growth catalysts still in development include NESP (in phase 3 for dialysis anemia), SD/01 and STEMGEN(R), with STEMGEN(R) pending FDA concerns despite a favorable advisory committee vote. Investors should also weigh policy risk: the Clinton administration proposed a 10% cut to Medicare EPOGEN(R) reimbursement and a reduction in NEUPOGEN(R) reimbursement basis from 95% to 83% of AWP. Litigation and regulatory exposure remain significant. The Johnson & Johnson arbitrations are ongoing, with Amgen winning the NESP arbitration in December 1998 and recovering costs as part of the award, although J&J is contesting those costs. Biogen and Genentech patent suits over NEUPOGEN(R) and INFERGEN(R) are unresolved, and a $400 million+ FoxMeyer-related claim is pending. The company is also not yet Year 2000 compliant, with a $40-60 million remediation budget and some projects behind schedule. Management has consistently characterized the outcome of these matters as not material to the financial statements.
Mar 16, 1999
1997-A
AMGEN INC Annual Report (Amendment), Year Ended Dec 31, 1997
This filing is Amendment No. 1 to Amgen Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 1997, filed May 8, 1998. It does not contain a full set of operating results or a narrative business review. Its stated purpose is to add restated financial data schedules (Exhibit 27 series) that reflect the company's adoption of SFAS No. 128, Earnings Per Share, which required retroactive restatement of EPS for prior periods. The amendment also corrects certain amounts in the financial data schedules to conform with Regulation S-K Item 601(c), Appendix A. Investors should treat it as a supplemental, technical correction rather than a new source of performance information. The cover page shows an aggregate market value of voting and non-voting stock held by non-affiliates of approximately $13.38 billion as of February 28, 1998, with 255,754,703 common shares outstanding on that date. Roughly 3.9 million shares were held by directors, officers, and 5%+ holders and were excluded from the market value calculation. The exhibit index shows the scale of Amgen's late-1990s activity, including a Heads of Agreement with F. Hoffmann-La Roche relating to G-CSF/EU rights, a binding term sheet with Guilford Pharmaceuticals dated August 1997, a 6.50% Notes due 2007, and an 8-1/8% Debentures due 2097, along with a credit agreement and commercial paper program. The filing is largely a reference document: most exhibits were previously filed with the original 10-K on March 24, 1998, and it incorporates Part III information by reference from the definitive 1998 proxy statement. Financial results, segment detail, and management discussion must be taken from the initial Form 10-K rather than this amendment. The primary investor takeaway is that the company's per-share figures for prior periods were recast under SFAS 128, so historical EPS comparisons should use the restated schedules.
May 8, 1998
1997
AMGEN INC Annual Report, Year Ended Dec 31, 1997
Amgen's 1997 10-K shows a company still dominated by two products, with growth decelerating sharply. Total 1997 revenues rose 7% to $2,401.0 million, but net income fell 5% to $644.3 million (diluted EPS $2.35 vs. $2.42), primarily because of a $157 million pre-tax legal assessment tied to the Johnson & Johnson arbitration over Epoetin alfa 'spillover' sales (about $0.35 per share). Excluding that charge, earnings grew, and the company's operating margin before the charge was roughly 36%, reflecting its strong gross margins on product sales (about 86%). The revenue mix is concentrated: EPOGEN (about 48% of revenue) and NEUPOGEN (about 44%) together account for over 90% of total revenue. EPOGEN growth slowed to 8% in 1997 because of HCFA's September 1997 dialysis reimbursement changes, and management guided to only single-digit product sales growth for 1998. NEUPOGEN sales grew just 4%, pressured by EU cost-containment policies, currency effects, and the shift away from off-label AIDS use. INFERGEN, launched in October 1997, contributed just $3.4 million in its first partial quarter. Balance-sheet strength remains a key positive: operations generated $902.9 million in cash, and the company ended 1997 with $1,026.5 million in cash and marketable securities. It spent $737.9 million repurchasing 13.7 million shares and raised $200 million of new debt, bringing long-term debt to $259 million. Research and development spending rose 19% to $630.8 million, and capital expenditures reached $387.8 million, both signaling continued heavy investment. Key risks include the unresolved Johnson & Johnson arbitrations (including NESP rights, with trial set for July 1998), patent litigation with Biogen, Genentech, Schering and Transkaryotic, and the FoxMeyer suit seeking at least $400 million.
Mar 24, 1998
1996
AMGEN INC Annual Report, Year Ended Dec 31, 1996
Amgen's 1996 10-K shows a biotech company at a high point of commercial momentum. Total revenues rose 15% to $2,239.8 million and net income reached $679.8 million, or $2.42 per primary share, up from $537.7 million ($1.92) in 1995. Operating cash flow was $822.6 million, and year-end cash and marketable securities totaled $1,077 million. Two products drive the business: EPOGEN (epoetin alfa), up 21% to $1,071.9 million and now 48% of revenue, and NEUPOGEN (filgrastim), up 9% to $1,016.3 million and 45% of revenue. Management guides to slower growth in both products in 1997, while still expecting double-digit growth in total product sales and earnings. The main investor concerns are concentration and legal exposure. Two products account for roughly 93% of revenue, and the company faces pressure from Medicare reimbursement policy for EPOGEN and from cost-containment efforts. Large litigation is pending, most notably an arbitration with Johnson & Johnson in which J&J seeks about $423 million (including interest) on EPOGEN sales, against Amgen's claim for about $12.6 million. Amgen also faces a $400 million-plus suit from FoxMeyer and a qui tam False Claims Act suit that management says could have a material adverse effect if the outcome is unfavorable. Management describes these as uncertain but states that most other matters are not expected to be material. The balance sheet strengthened, with stockholders' equity up to $1,906.3 million and long-term debt down to $59.0 million. The company repurchased $450 million of stock in 1996 and plans up to $450 million more in 1997, partly hedged with put warrants and call options. The pipeline includes INFERGEN (consensus interferon) pending regulatory approval, NESP and MGDF in clinical development through the Kirin-Amgen joint venture, and early-stage leptin and neurobiology programs. Research and development spending rose 17% to $528.3 million, which is an investment in future growth that could pressure near-term margins.
Mar 24, 1997
1995
AMGEN INC Annual Report, Year Ended Dec 31, 1995
Amgen's 1995 annual report shows a company with strong top-line growth and a sharp rebound in profitability. Total revenues rose 18% to $1.94 billion, driven by product sales of $1.82 billion (up 17%). EPOGEN, the anemia treatment for dialysis patients, grew 22% to $882.6 million, and NEUPOGEN, the neutrophil-stimulating product, grew 13% to $936.0 million. Net income more than doubled to $537.7 million, or $1.92 per primary share, compared with $319.7 million in 1994. The 1994 figure absorbed a $116.4 million write-off tied to the Synergen acquisition, so the underlying improvement is smaller than the headline suggests, but operating income still rose about 28% to $743.6 million. Management expects 1996 product sales and earnings to grow at double-digit rates, though slower than in 1995, citing cost-containment pressure on NEUPOGEN and dialysis reimbursement risk for EPOGEN. The balance sheet and cash generation are solid. Operating cash flow was $773.2 million, cash and marketable securities totaled $1.05 billion, and long-term debt was modest at $177.2 million against stockholders' equity of $1.67 billion. Amgen plans to spend $350 to $450 million repurchasing stock in 1996 and $250 to $350 million per year on capital projects. R&D spending rose 40% to $451.7 million, and management plans faster R&D growth than sales growth. Research pipeline items include INFERGEN, BDNF for ALS, MGDF for platelet production, and Leptin, which is expected to enter human trials in 1996. The main investor concern is legal exposure. The most significant matter is the arbitration with Johnson & Johnson over EPOGEN sales allocation. Amgen seeks about $10 million for 1989 through 1994, while J&J seeks about $419 million, and a trial was scheduled for March 1996. Amgen has also sought termination of J&J's license. Other matters include the Genetics Institute and Biogen patent suits, Elanex patent litigation, and securities suits related to the Synergen ANTRIL program. Management says none of these is expected to have a material adverse effect on the financial statements, but the J&J outcome could change how EPOGEN sales are recognized in prior periods.
Mar 29, 1996
1994
AMGEN INC Annual Report, Year Ended Dec 31, 1994
Amgen's 10-K for fiscal 1994 shows a biotechnology company still driven almost entirely by two products: NEUPOGEN (filgrastim, roughly 50% of revenues) and EPOGEN (epoetin alfa, roughly 44%). Total revenues rose 20% to $1,647.9 million, and product sales grew 19% to $1,549.6 million. Operating cash flow was strong at $531.9 million, and cash plus marketable securities totaled $696.7 million at year-end. Stockholders' equity reached $1,274.3 million, and the company carries modest long-term debt of $183.4 million. Reported net income fell 17% to $319.7 million, or $2.29 per primary share, but this decline is largely due to a non-deductible $116.4 million write-off of in-process technology tied to the December 1994 acquisition of Synergen for $254.5 million. Excluding that charge, earnings would have grown meaningfully. Management guided to double-digit growth in 1995 for both NEUPOGEN and EPOGEN, though at rates below 1994's, and expects R&D spending to grow faster than sales. The Synergen deal also brings lawsuits from former Synergen shareholders and warrant holders, and the company is involved in an arbitration with Johnson & Johnson over EPOGEN sales accounting, with a trial set for October 1995. Key risks for investors include concentration in two products, U.S. healthcare reform and reimbursement changes (EPOGEN is largely reimbursed through Medicare's ESRD program), dependence on two wholesale distributors (22% and 16% of revenue), the unresolved Johnson & Johnson arbitration, and patent litigation including a Biogen suit over NEUPOGEN. Amgen has no dividend and intends to retain earnings and continue repurchasing stock, with $331.2 million of authorization remaining.
Mar 30, 1995